Parkinson's Disease (PD) is a progressive neurodegenerative disorder that predominantly affects the dopaminergic neurons in the substantia nigra, causing motor and non-motor symptoms. The pathogenesis of PD is multifactorial, involving genetic and environmental factors. This complex disorder requires a comprehensive understanding for optimal patient management.
PD affects approximately 1% of individuals over the age of 60, with a higher prevalence in males. Risk factors include age, genetic predisposition, exposure to certain pesticides, and history of head injury. Conversely, caffeine intake and tobacco use appear to have a protective effect.
The hallmark of PD is the loss of dopaminergic neurons in the substantia nigra pars compacta, leading to dopamine deficiency in the striatum. This results in an imbalance in the direct and indirect pathways of the basal ganglia, causing motor symptoms. The presence of Lewy bodies, composed of alpha-synuclein, is another characteristic feature.
PD presents with both motor (bradykinesia, rigidity, rest tremor, postural instability) and non-motor symptoms (depression, constipation, sleep disturbances). Diagnosis is primarily clinical, supported by response to dopaminergic therapy. Neuroimaging can aid in differentiating PD from other parkinsonian syndromes.
Treatment of PD is symptomatic, with levodopa being the most effective medication for motor symptoms. Non-motor symptoms are managed with a multidisciplinary approach. Deep brain stimulation can be considered in patients with motor complications not adequately controlled by medication.
PD is a complex neurodegenerative disorder with a multifactorial pathogenesis. A comprehensive understanding of its epidemiology, pathophysiology, clinical presentation, and treatment options is essential for healthcare professionals to provide optimal patient care.
1.
Combo Therapy Boosts Early CML Response but Not Long Term
2.
PNH With Extravascular Hemolysis Approves Factor D Inhibitor.
3.
In a long-term comparison with adjuvant RT, salvage radiotherapy after prostateectomy is the most successful treatment.
4.
AI Breath Test IDs Cancers; More Grief for Prior Auth; Imatinib Discoverer Resigns
5.
Classifying childhood brain cancers by immune response may improve diagnostics and treatments
1.
Precision Oncology: Integrating Genomics and Data to Shape Cancer Care’s Future
2.
Decoding Hamartomas: Understanding Their Causes and Symptoms
3.
Understanding the Silent Threat: Unveiling Prostate Cancer Symptoms
4.
Battling Blood Cancers: Advances in HIV-Related Hematologic Malignancies in the ART Era
5.
Breaking Barriers: Innovative Approaches in Brain Tumor Treatment
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Effect of Pablociclib in Endocrine Resistant Patients - A Panel Discussion
2.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Final Discussion
3.
Efficient Management of First line ALK-rearranged NSCLC
4.
Updates on Standard V/S High Risk Myeloma Treatment- The Next Part
5.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation